论文部分内容阅读
高级别胶质瘤是最常见且恶性程度最高的中枢神经系统恶性肿瘤,复发后的侵袭性更强,常规放化疗的疗效不佳。贝伐单抗是批准用于治疗复发性胶质瘤的一种抗血管内皮生长因子单克隆抗体。近年来,开展了许多有关贝伐单抗联合其他治疗手段治疗复发性高级别胶质瘤的临床研究,但对于联合用药的疗效、模式及安全性尚存有较多争议。本文对贝伐单抗应用于复发性高级别胶质瘤治疗的最新进展进行综述,以期为临床上使用贝伐单抗治疗复发性高级别胶质瘤提供参考。
High-grade gliomas are the most common and malignant malignant tumors of the central nervous system with more aggressive post-relapse and poor efficacy of conventional chemoradiation. Bevacizumab is a monoclonal antibody against vascular endothelial growth factor approved for the treatment of recurrent gliomas. In recent years, many clinical researches about bevacizumab in combination with other therapies for the treatment of recurrent high-grade gliomas have been conducted. However, there are still many controversies about the efficacy, mode and safety of combination therapy. This review summarizes the recent advances in the treatment of recurrent high-grade glioma by bevacizumab in order to provide a reference for the clinical use of bevacizumab in the treatment of recurrent high-grade gliomas.